Gilead to acquire Ouro Medicines for clinical BCMAxCD3 program
Gilead Sciences plans to buy Ouro Medicines for up to $2.175bn, adding OM336, a clinical BCMAxCD3 T cell engager for autoimmune diseases.
Image: Gilead
Jenoptik appoints Dr. Dominic Dorfner as future CEO
Jenoptik’s Supervisory Board has appointed Dr. Dominic Dorfner as future CEO. He is expected to take office no later than 1 October 2026.
Stefan Betzold to leave Bauer Media Group
Stefan Betzold is leaving Bauer Media Group. The Managing Director of Bauer Xcel Media will support the transition of responsibilities.
Hims & Hers shifts US weight loss strategy with Novo Nordisk deal
Hims & Hers is refocusing its US weight loss business and teaming up with Novo Nordisk, prioritizing access to a wider set of FDA-approved GLP-1 drugs.
Veeva acquires Ostro to expand AI-driven brand engagement
Veeva Systems is acquiring Ostro for about $100 million. The AI chat platform targets compliant brand websites and engagement insights for life sciences.
Sandoz launches azelastine/fluticasone nasal spray in Germany and Switzerland
Sandoz has launched an azelastine/fluticasone nasal spray in Germany and Switzerland, expanding access to a fixed-dose allergy treatment option.
Christopher Kirsch appointed chair of Pro Biosimilars
Dr. Christopher Kirsch (Sandoz/Hexal) has been appointed chair of Pro Biosimilars. Dominic Fister (STADAPHARM) will serve as deputy chair.
Lilly opens interactive obesity experience in Berlin
Lilly Deutschland has opened an interactive obesity experience at Berlin’s Masumi Space. The installation runs from 2 to 8 March 2026.
NOWEDA relaunches LED truck tour for its pharmacy campaign
Ahead of 23 March, NOWEDA sends an LED truck with its “Apotheken stärken. Jetzt” campaign to several major German cities.
Sandoz partners with Samsung Bioepis on up to five biosimilars
Sandoz and Samsung Bioepis agreed to collaborate on up to five biosimilar assets, starting with an early-stage vedolizumab biosimilar program.